2006
DOI: 10.1021/jm0603926
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis, Crystal Structure, Structure−Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor

Abstract: A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG-0205221, K i ) 53 nM) has been developed. TG-0205221 showed remarkable activity against SARS CoV and human coronavirus (HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 µM) for SARS CoV and 5.2 log (at 1.25 µM) for HCoV 229E. The crystal structure of TG-0205221 (resolution ) 1.93 Å) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
172
0

Year Published

2007
2007
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 150 publications
(175 citation statements)
references
References 20 publications
3
172
0
Order By: Relevance
“…Peptide and peptidomimetic aldehyde inhibitors against 3CL pro have been reported (Akaji et al, 2008(Akaji et al, , 2011Zhu et al, 2011) but not tested on live CoVs. However, a potent SARS-CoV 3CL pro peptidomimetic aldehyde inhibitor, TG-0205221, has been shown to block SARS-CoV and human CoV 229E replications (Yang et al, 2006). As shown in this study, we have identified potent and membranepermeable MERS-CoV inhibitors 6b, 6c and 6d using live MERS-CoV virus with EC 50 of 0.6e1.2 mM and S.I.…”
Section: Broad Spectrum Activity Against Human and Feline Covsmentioning
confidence: 62%
See 1 more Smart Citation
“…Peptide and peptidomimetic aldehyde inhibitors against 3CL pro have been reported (Akaji et al, 2008(Akaji et al, , 2011Zhu et al, 2011) but not tested on live CoVs. However, a potent SARS-CoV 3CL pro peptidomimetic aldehyde inhibitor, TG-0205221, has been shown to block SARS-CoV and human CoV 229E replications (Yang et al, 2006). As shown in this study, we have identified potent and membranepermeable MERS-CoV inhibitors 6b, 6c and 6d using live MERS-CoV virus with EC 50 of 0.6e1.2 mM and S.I.…”
Section: Broad Spectrum Activity Against Human and Feline Covsmentioning
confidence: 62%
“…Though 3C pro and 3CL pro share similar structures at their active sites, subtle differences often discriminate inhibitors. AG7088, an established 3C pro inhibitor, was inactive against SARS-CoV 3CL pro prior to the modifications (Ghosh et al, 2005;Shie et al, 2005;Thanigaimalai et al, 2013;Yang et al, 2006). Unlike AG7088 which contains a, b-unsaturated ester for forming covalent bond with the active-site Cys, our previously reported potent peptidomimetic inhibitors of 3C pro from enterovirus 71 (EV71) contains aldehyde as electrophilic warhead (Kuo et al, 2008).…”
Section: Introductionmentioning
confidence: 99%
“…AG7088 itself was found to be inactive in enzyme assays with SARS-CoV M pro ; however, modifications to the peptidomimetic scaffold lead to significant inhibition potencies. [8,9] The electrophilic building block of these active-site-directed inhibitors consists of an a,b-unsaturated ester function, which undergoes nucleophilic attack by the thiol group of the cysteine residue.…”
Section: Introductionmentioning
confidence: 99%
“…A few non-covalent, competitive inhibitors 10 and peptidic, covalent inhibitors have been visualized in SARS 3CL pro crystal structures. 7,8,[11][12][13] The covalent inhibitors studied to date carry either a halomethyl ketone, an epoxide or a 1,4 Michael acceptor function as the reactive "warheads". Such functionalities permanently inactivate the viral peptidase via the formation of a nonhydrolysable covalent linkage to Cys145 as the result of the nucleophilic attack by its S γ atom.…”
Section: Introductionmentioning
confidence: 99%